Science
Projects
Scientific Interest
Our research focuses on the histone methyltransferase KMT9 that plays a role in regulating gene activity and cell proliferation and is a potential therapeutic target for new treatments in prostate and bladder cancers.
We developed first-in-class, highly potent and selective KMT9 inhibitors that impair proliferation of tumour cell in vitro and in vivo in animal models.
Recently, we identified KMT9 as a major regulator of immunosuppression in prostate cancer and our findings suggest that targeting KMT9 sensitizes prostate cancer to immune checkpoint therapy.
Our methodology uses molecular analyses, transgenic mice, and knockout mouse models to investigate the role of KMT9 in human diseases.